Patients’ Own Coenzyme Q10
Coenzyme Q10 (known as CoQ10) is a substance which helps to procure energy from food. It is also a powerful antioxidant, which helps to boost immunity by increasing the number of particular immune cells present in the body. For these reasons, taking a CoQ10 dietary supplement for Chronic Fatigue Syndrome and Fibromyalgia is recommended.
Following the age of 20, levels of CoQ10 begin to fall as dietary CoQ10 is absorbed less efficiently from the intestines. Low levels of CoQ10 mean that cells do not receive all the energy they require.
CoQ10 is one of the most popular supplements for Chronic Fatigue Syndrome and Fibromyalgia patients, due to its positive impact on energy production, fighting free radicals and immunity.
The following Chronic Fatigue Syndrome specialists recommend taking Coenzyme Q10 dietary supplements for CFS: Dr Cheney, Dr Teitelbaum, Dr Pall, Dr Downing-Orr and Dr Myhill.
The science behind treating CFS and Fibro with CoQ10
Co-enzyme Q10 significantly reduces fatigue in ME/CFS patients
A 2015 Spanish randomized, double-blind placebo-controlled trial study evaluated the benefits of CoQ10 and NADH supplementation on fatigue and biochemical parameters in 73 Spanish CFS patients. They found that NADH combined with Coenzyme Q10 significantly improved fatigue compared with the placebo group. In addition, a recovery of the biochemical parameters was also reported.
A study published in Clinical Nutrition in 2016 assessed whether NADH and Coenzyme Q10 supplementation showed a significant reduction in maximum heart rate after a cycle ergometer test. The 8-week, randomized, controlled, double-blind trial was conducted on 80 Chronic Fatigue Syndrome patients. The CoQ10 plus NADH group showed a significant reduction in max HR during a cycle ergometer test at week 8 versus baseline. Perception of fatigue also showed a decrease through all follow-up visits in active group versus placebo.
Chronic Fatigue Syndrome patients have low levels of CoQ10
A 2009 study conducted by Maes et al. assessed plasma CoQ10 levels in 58 patients with ME/CFS and in 22 normal controls and the relationships between CoQ10 and the severity of ME/CFS. They discovered that plasma CoQ10 was significantly lower in ME/CFS patients than in healthy controls. Furthermore, there was a significant inverse relationship between CoQ10 levels and fatigue and autonomic symptoms. The authors conclude that CoQ10 depletion plays a role in the pathophysiology of ME/CFS and suggest that patients would benefit from CoQ10 supplementation.
Co-Enzyme Q10 supplements can reduce symptoms in Fibro patients
Cordero et al. 2012 examined oxidative stress and bioenergetic status in blood mononuclear cells (BMCs) and its association to headache symptoms in 20 Fibromyalgia (FM) patients and 15 healthy controls. They found decreased CoQ10, catalase and ATP levels in BMCs from FM patients as compared to normal controls. Significant negative correlations between CoQ(10) or catalase levels in BMCs and headache parameters were also observed. Oral supplementation of COQ10 restored biochemical parameters and significantly improved clinical and headache symptoms. This study followed two pilot studies conducted by the same authors which also found CoQ10 deficiencies in FM patients and an improvement in symptoms after oral supplementation and restoration of CoQ10 levels.
A 2013 trial by Cordero et al. investigated the effect of CoQ10 supplementation on Fibromyalgia (FM) patients. A randomized, double-blind, placebo-controlled trial to evaluate clinical and gene expression effects of forty days of CoQ10 supplementation (300 mg/day) on 20 FM patients was undertaken. An important clinical improvement was evident after CoQ10 versus placebo treatment showing a reduction of pain, fatigue, and morning tiredness. Furthermore, an important reduction in tender points, including recovery of inflammation, antioxidant enzymes, mitochondrial biogenesis, and gene expression levels was observed. The authors conclude that CoQ10 has a potential therapeutic effect in Fibromyalgia, and indicate new potential molecular targets for the therapy of this disease.
A 2002 trial published in The Journal of International Medical Research evaluated the efficacy of CoQ10 and ginkgo biloba supplementation on Fibromyalgia patients. Subjects were given oral doses of 200 mg coenzyme Q10 and 200 mg Ginkgo biloba extract daily for 84 days. Quality of life was measured using seven different subjective responses at monthly intervals. A progressive improvement in the quality-of-life scores was observed over the study period and at the end, the scores showed a significant difference from those at the start. This was matched by an improvement in self-rating with 64% claiming to be better.
A Low level of CoQ10 is found in Fibromyalgia patients
In 2014, Cordero et al. investigated the role of coenzyme Q10 (CoQ10) deficiency and mitochondrial dysfunction in immune activation in Fibromyalgia (FM) patients. Mitochondrial dysfunction was accompanied by increased levels of pro-inflammatory cytokines. A placebo-controlled trial of CoQ10 in FM patients led to reduced immune activation.
In 2013, Alcocer-Gomez et al. conducted a small study on four Fibromyalgia patients. All patients showed CoQ10 deficiency and improvement in clinical symptoms across all evaluation methods after CoQ10 supplementation.